Patients with a history of cancer who receive tumor necrosis factor inhibitors for rheumatoid arthritis may not be at increased risk for recurrence, suggests a Swedish population-based study.
Eric J Gapud and Philip Seo summarize the key milestones in management of severe granulomatosis with polyangiitis, and evaluate the possibility of long-term reduced intensity or drug-free remission for some patients.
31-07-2018 | Pain disorders | View from the clinic | Article
Results of a phase III trial indicate that both the immediate and extended release formulations of febuxostat reduce serum uric acid levels in patients with gout, including those with impaired renal function.
Patients with a history of cancer who receive tumor necrosis factor inhibitors for rheumatoid arthritis may not be at increased risk for recurrence, suggests a Swedish population-based study.
Collaboration between rheumatologists and dermatologists in a combined clinic may help improve outcomes for patients with psoriatic arthritis, study results suggest.
The chances of patients with early rheumatoid arthritis not responding to methotrexate treatment at 6 months increase significantly with increasing disease activity during the first 12 weeks, study findings indicate.
Source:
Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213502
Results of a phase III trial indicate that the infliximab biosimilar PF-06438179/GP1111 has similar efficacy, safety, and immunogenicity profiles to its reference product.
Patients with newly diagnosed systemic lupus erythematosus may experience changes to the cardiac extracellular matrix that are indicative of subclinical cardiac impairment, researchers report.
